Anti-drug antibodies Archives - ACR Meeting Abstracts

Abstract Number: 1525 • ACR Convergence 2021
Risk Factors for Anti-infliximab Antibody Formation: Results from a Randomized Controlled Trial
Marthe Brun¹, Guro Goll¹, Kristin Jørgensen², Joseph Sexton¹, Johanna Gehin³, Øystein Sandanger⁴, Inge Olsen⁴, Rolf Anton Klaasen⁴, David Warren⁴, Cato Mørk⁵, Tore Kvien¹, Jørgen Jahnsen², Nils Bolstad⁴, Espen Haavardsholm¹ and Silje Watterdal Syversen¹, ¹Diakonhjemmet Hospital, Oslo, Norway, ²Akershus University Hospital, Lørenskog, Norway, ³Oslo University Hospital, Lillehammer, Nepal, ⁴Oslo University Hospital, Oslo, Norway, ⁵Akershus Dermatology Center, Lørenskog, Norway
Background/Purpose: Immunogenicity is related to loss of efficacy and safety to TNFα inhibitors and is frequently observed early in the treatment course. The highest rate…
Abstract Number: 586 • ACR/ARP Annual Meeting 2019
Drug Concentrations and Anti-drug Antibodies Influence in Response to Adalimumab: Results from the BioEfficacySpA Clinical Trial
José Marona¹, Santiago Rodrigues-Manica ², João Lagoas Gomes ¹, Carina Lopes ³, Inês Iria ⁴, Miguel Bernardes ⁵, Helena Santos ⁶, Jose Tavares-Costa ⁷, João Madruga-Dias ⁸, Patrícia Pinto ⁹, Alexandra Bernardo ¹⁰, Sara Maia ¹¹, Jaime Branco ², João Gonçalves ⁴ and Fernando Pimentel-Santos ², ¹Rheumatology Department, Hospital de Egas Moniz, Centro Hospitalar de Lisboa Ocidental; CEDOC, NOVA Medical School, Faculdade de Ciências Médicas, Lisbon., Lisbon, Portugal, ²CEDOC, NOVA-Medical School | Hospital Egas Moniz, CHLO, Lisbon, Lisbon, Portugal, ³Rheumatology Department, Hospital de Egas Moniz, Centro Hospitalar de Lisboa Ocidental; CEDOC, NOVA Medical School, Faculdade de Ciências Médicas, Lisbon, Lisbon, Portugal, ⁴Faculdade de Farmácia da Universidade de Lisboa; Portugal, Lisbon, Portugal, ⁵Rheumatology, Centro Hospitalar de São João, Porto, Portugal, Porto, Portugal, ⁶Instituto Português de Reumatologia (IPR), Lisbon, Portugal, ⁷ULSAM, Ponte de Lima, Portugal, Ponte de Lima, Portugal, ⁸CHMT, Torres Novas, Portugal, Torres Novas, ⁹Rheumatology Department, CHVNG, Vila Nova de Gaia, Portugal, ¹⁰Rheumatology Department, CHSJ, Porto, Portugal, ¹¹CEDOC, NOVA Medical School, Faculdade de Ciências Médicas, Lisbon, Lisbon, Portugal
Background/Purpose: Almost all protein-based biotherapeutics can induce immunogenicity, which may result in loss of efficacy and/or increased risk of adverse reactions. Despite all the efforts…

Abstracts tagged "Anti-drug antibodies"

Risk Factors for Anti-infliximab Antibody Formation: Results from a Randomized Controlled Trial

Drug Concentrations and Anti-drug Antibodies Influence in Response to Adalimumab: Results from the BioEfficacySpA Clinical Trial